The Current Ratio as of November 2024 (TTM) for Eiger BioPharmaceuticals, Inc. (EIGR) is 0.71

According to Eiger BioPharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 0.71. This represents a change of -76.85% compared to the average of 3.07 of the last 4 quarters.

Eiger BioPharmaceuticals, Inc. (EIGR) Historical Current Ratio (quarterly & annually)

How has EIGR Current Ratio performed in the past?

The mean historical Current Ratio of Eiger BioPharmaceuticals, Inc. over the last ten years is 7.85. The current 0.71 Current Ratio has changed 804.50% with respect to the historical average. Over the past ten years (40 quarters), EIGR's Current Ratio was at its highest in in the September 2015 quarter at 21.20. The Current Ratio was at its lowest in in the December 2023 quarter at 0.71.

Eiger BioPharmaceuticals, Inc. (EIGR) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Eiger BioPharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Eiger BioPharmaceuticals, Inc. (EIGR) Average Current Ratio

How has EIGR Current Ratio performed in the past?

The current Current Ratio of Eiger BioPharmaceuticals, Inc. (EIGR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Eiger BioPharmaceuticals, Inc. (EIGR) Current Ratio vs. Peers

How is EIGR’s Current Ratio compared to its peers?

Eiger BioPharmaceuticals, Inc.’s Current Ratio is less than Spero Therapeutics, Inc. (2.68), less than Bolt Biotherapeutics, Inc. (4.28), less than Coherus BioSciences, Inc. (1.21), less than Gracell Biotechnologies Inc. (7.73), less than Neoleukin Therapeutics, Inc. (15.33), less than Cingulate Inc. (1.20), less than Lyra Therapeutics, Inc. (3.60), less than Finch Therapeutics Group, Inc. (3.87), less than Applied Therapeutics, Inc. (2.30), less than X4 Pharmaceuticals, Inc. (6.07), less than Acumen Pharmaceuticals, Inc. (17.37), less than Inozyme Pharma, Inc. (9.84), less than Terns Pharmaceuticals, Inc. (21.02), less than Day One Biopharmaceuticals, Inc. (14.62), less than Connect Biopharma Holdings Limited (12.04), less than Eton Pharmaceuticals, Inc. (1.40), less than Nuvation Bio Inc. (11.49), less than Eledon Pharmaceuticals, Inc. (14.48), less than Spruce Biosciences, Inc. (5.17), less than Werewolf Therapeutics, Inc. (12.13), less than Unicycive Therapeutics, Inc. (3.37), less than Fusion Pharmaceuticals Inc. (10.64),

Build a custom stock screener for Eiger BioPharmaceuticals, Inc. (EIGR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Eiger BioPharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Eiger BioPharmaceuticals, Inc. (EIGR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Eiger BioPharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.